Kinetics of plasma cytokines and chemokines during primary HIV-1 infection and after analytical treatment interruption

HIV Medicine

Volumn 10, Issue 2, 2009, Pages 94-102

  Barqasho, Babilonia ^a   Nowak, P ^a   Tjernlund, A ^a   Kinloch, S ^b   Goh, L E ^c   Lampe, F ^b   Fisher, M ^d   Andersson, J ^a   Sonnerborg A ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d UK   (United Kingdom)

Author keywords

Chemokines; Cytokines; HIV 1; Innate immunity; Primary HIV 1 infection

Indexed keywords

ABACAVIR; ALVAC HIV; AMPRENAVIR; ANTIRETROVIRUS AGENT; CHEMOKINE; CP 1452; CYTOKINE; EOTAXIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 6; LAMIVUDINE PLUS ZIDOVUDINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; AREA UNDER THE CURVE; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; KINETICS; LYMPHOCYTE COUNT; MALE; MONOTHERAPY; PRIMARY INFECTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; VIRAL LOAD; WITHHOLDING TREATMENT;

EID: 68949083594     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00657.x     Document Type: Article

References (38)

1. Douek DC, Betts MR, Hill BJ et al. Evidence for increased T cell turnover and decreased thymic output in HIV infection. J Immunol 2001; 167: 6663-6668.
2. Brenchley JM, Price DA, Douek DC. HIV disease: Fallout from a mucosal catastrophe? Nat Immunol 2006; 7: 235-239.
3. Berrey MM, Schacker T, Collier AC et al. Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. J Infect Dis 2001; 183: 1466-1475.
4. Kaufmann GR, Zaunders JJ, Cunningham P et al. Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection. AIDS 2000; 14: 2643-2651.
5. Kedzierska K, Crowe SM. Cytokines and HIV-1: Interactions and clinical implications. Antivir Chem Chemother 2001; 12: 133-150.
6. Sinicco A, Biglino A, Sciandra M et al. Cytokine network and acute primary HIV-1 infection. AIDS 1993; 7: 1167-1172.
7. Biglino A, Sinicco A, Forno B et al. Serum cytokine profiles in acute primary HIV-1 infection and in infectious mononucleosis. Clin Immunol Immunopathol 1996; 78: 61-69.
8. Amicosante M, Poccia F, Gioia C et al. Levels of interleukin-15 in plasma may predict a favorable outcome of structured treatment interruption in patients with chronic human immunodeficiency virus infection. J Infect Dis 2003; 188: 661-665.
9. Goh LE, Perrin L, Hoen B et al. Study protocol for the evaluation of the potential for durable viral suppression after quadruple HAART with or without HIV vaccination: The QUEST Study. HIV Clin Trials 2001; 2: 438-444.
10. Kinloch-de Loes S, Hoen B, Smith DE et al. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis 2005; 192: 607-617.
11. Schockmel GA, Yerly S, Perrin L. Detection of low HIV-1 RNA levels in plasma. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14: 179-183.
12. Salazar-Gonzalez JF, Martinez-Maza O, Nishanian P et al. Increased immune activation precedes the inflection point of CD4 T cells and the increased serum virus load in human immunodeficiency virus infection. J Infect Dis 1998; 178: 423-430.
13. Fahey JL, Taylor JM, Manna B et al. Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements. AIDS 1998; 12: 1581-1590.
14. Appay V, Boutboul F, Autran B. The HIV infection and immune activation: 'to fight and burn'. Curr Infect Dis Rep 2005; 7: 473-479.
15. Lindback S, Karlsson AC, Mittler J et al. Viral dynamics in primary HIV-1 infection. Karolinska Institutet Primary HIV Infection Study Group. AIDS 2000; 14: 2283-2291.
16. Hel Z, McGhee JR, Mestecky J. HIV infection: First battle decides the war. Trends Immunol 2006; 27: 274-281.
17. Mellors JW, Munoz A, Giorgi JV et al. Plasma viral load and CD4 lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: 946-954.
18. Birk M, Svedhem V, Sonnerborg A. Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy. AIDS 2001; 15: 1359-1368.
19. Betts MR, Nason MC, West SM et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8 T cells. Blood 2006; 107: 4781-4789.
20. Polo S, Veglia F, Malnati MS et al. Longitudinal analysis of serum chemokine levels in the course of HIV-1 infection. AIDS 1999; 13: 447-454.
21. Aleman S, Pehrson P, Sonnerborg A. Kinetics of beta-chemokine levels during anti-HIV therapy. Antivir Ther 1999; 4: 109-115.
22. Bisset LR, Rothen M, Joller-Jemelka HI, Dubs RW, Grob PJ, Opravil M. Change in circulating levels of the chemokines macrophage inflammatory proteins 1 alpha and 11 beta, RANTES, monocyte chemotactic protein-1 and interleukin-16 following treatment of severely immunodeficient HIV-infected individuals with indinavir. AIDS 1997; 11: 485-491.
23. Aukrust P, Muller F, Froland SS. Circulating levels of RANTES in human immunodeficiency virus type 1 infection: Effect of potent antiretroviral therapy. J Infect Dis 1998; 177: 1091-1096.
24. Ye P, Kazanjian P, Kunkel SL, Kirschner DE. Lack of good correlation of serum CC-chemokine levels with human immunodeficiency virus-1 disease stage and response to treatment. J Lab Clin Med 2004; 143: 310-319.
25. Brichacek B, Bukrinsky M. Highly active antiretroviral therapy and beta-chemokines. Clin Exp Immunol 2002; 130: 169-171.
26. Torti C, Cologni G, Uccelli MC et al. Immune correlates of virological response in HIV-positive patients after highly active antiretroviral therapy (HAART). Viral Immunol 2004; 17: 279-286.
27. Falcone C, Minoretti P, D'Angelo A et al. Markers of eosinophilic inflammation and risk prediction in patients with coronary artery disease. Eur J Clin Invest 2006; 36: 211-217.
28. Targowski T, Jahnz-Rozyk K, Plusa T, Glodzinska-Wyszogrodzka E. Influence of age and gender on serum eotaxin concentration in healthy and allergic people. J Investig Allergol Clin Immunol 2005; 15: 277-282.
29. Tacke F, Trautwein C, Yagmur E et al. Up-regulated eotaxin plasma levels in chronic liver disease patients indicate hepatic inflammation, advanced fibrosis and adverse clinical course. J Gastroenterol Hepatol 2006; 8: 1-9.
30. Culley FJ, Pennycook AMJ, Tregoning JS, Hussell T, Openshaw PJM. Differential chemokine expression following respiratory virus infection reflects Th1- or Th2-biased immunopathology. J Virol 2006; 80: 4521-4527.
31. He J, Chen Y, Farzan M et al. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature 1997; 385: 645-649.
32. Choe H, Farzan M, Sun Y et al. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996; 85: 1135-1148.
33. Modi WS, Goedert JJ, Strathdee S et al. MCP-1-MCP-3-Eotaxin gene cluster influences HIV-1 transmission. AIDS 2003; 17: 2357-2365.
34. Promadej-Lanier N, Srinivasan P, Curtis K et al. Systemic and mucosal immunological responses during repeated mucosal SHIV 162P3 challenges prior to and following infection in pigtailed macaques. Virology 2008; 375: 492-503.
35. Moanna A, Dunham R, Paiardini M, Silvestri G. CD4 T-cell depletion in HIV infection: Killed by friendly fire? Curr HIV/AIDS Rep 2005; 2: 16-23.
36. Bustin M. At the crossroads of necrosis and apoptosis: Signaling to multiple cellular targets by HMGB1. Sci STKE 2002; 151: PE39.
37. Wang H, Ward MF, Fan XG, Sama AE, Li W. Potential role of high mobility group box 1 in viral infectious diseases. Viral Immunol 2006; 19: 3-9.
38. Nowak P, Barqasho B, Sonnerborg A. Elevated plasma levels of high mobility group box protein 1 in patients with HIV-1 infection. AIDS 2007; 21: 869-871.